Durvalumab + Gemcitabine/Cisplatin
Treatment for Gallbladder and biliary tract cancer
Effectiveness
60%
Safety Score
28%
Clinical Trials
5
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
28
DangerousModerateSafe
Treatment Details
0
Durvalumab + Gemcitabine/Cisplatin Outcomes
for Gallbladder and biliary tract cancer
Efficacy Outcomes
Overall Effectiveness
+60%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
4 active trials recruiting for Durvalumab + Gemcitabine/Cisplatin in Gallbladder and biliary tract cancer
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253RECRUITINGPHASE3
1.1K participants
INTERVENTIONAL
Birmingham, United States +167 more
Started: Dec 4, 2025
Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer
NCT04308174ACTIVE NOT RECRUITINGPHASE2
45 participants
INTERVENTIONAL
Seoul, South Korea
Started: May 20, 2020
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575RECRUITINGPHASE3
286 participants
INTERVENTIONAL
Duarte, United States +183 more
Started: Jul 19, 2024
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
NCT05712356ACTIVE NOT RECRUITINGPHASE2
67 participants
INTERVENTIONAL
Gilbert, United States +18 more
Started: Aug 24, 2023
Completed Clinical Trials
1 completed trial for Durvalumab + Gemcitabine/Cisplatin in Gallbladder and biliary tract cancer
Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients
NCT03473574COMPLETEDPHASE2
128 participants
INTERVENTIONAL
Hanover, Germany
Started: May 2, 2018